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We have taken the opportunity of a clinical trial of the potential efficacy and safety of FK 506 
(tacrolimus) in chronic progressive multiple sclerosis (MS) to cxamine the intluencc of this potent ncw 
immunosuppressant on circulating T-lymphocytes in an otherwise healthy non-transplant population. 
Peripheral blood levels of subsets of C04 + T lymphocytes expressing the activation molecule 
interleukin-2 receptor (pSS a chain: C025) or the C045RA isoform were determined sequentially in 
19 patients that were treated continuously with oral FK 506 (starting dose 0.15 mglkglday) for 12 
months. No significant change in the proportion of circulating C025 . C04' cells was observed over 
the study period in which the mean trough plasma FK 506 level rose from 0.3 ± 0.2 to O.S ± 0,4 ng/ml. 
There was also no significant elrect of FK 506 on the percentage of C045 RA • C04' cells in the 
peripheral blood at 12 months compared with pretreatment values. Analysis of a suhgroup of 7 
patients. who showed a sustallH:d reduction In C025' C04' cells and a reciprocal increase ill 
C045RA' COol - cells lor at least 6 months alier start 01' treatment. Jid not rcveal any ditfcn:nce in 
disability at one year compared with the treatment group as a whole. The side dlccts of FK SOA were 
mIld and the overall degree of disability estimated by the mean Kurtzke cxpanded disahIlilY status 
scale (EOSS) score or the ambulation index did not deteriorate significantly ill the 19 patients studied 
o\'er the 12 months of FK 506 administration, 
KEY WORDS: Multiple sclerosis. FK SOA. immunosuppression. T cdls, 
ABBREVIATIONS: AI; ambulation index: eNS. central nervous system: EOSS. expanded disahilitv 
status s.:ale: mAh. 1110noclonal antibody: MHC. major histoc011lpatihilitv COI11-
plex: [\INC. mononuclear cells: MS. multiple sclerosis. 
INTRODUCTION 
The macrolide antibiotic FK 506 (tacrolimus) is a 
powerful new T-cell-directed immunosuppressive 
agent IK~ with a similar but considerably more potent 
anti-lymphocytic activity compared to eyclosporin A 
(CSA),1 A It suppresses sekctively. the transcription of 
interIcukin-2 (IL-21 and other cytokine genes in CD4 + 
T-cell'. and inhibits the induction of T-cell activation 
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'atlon Institute. UniversIt\ of Pittsburgh Medical Center. 
W 1544 Biomedical ScienCi.! Tllwcr. Pittsburgh. P,\ 15213 USA. 
T.:l: (412) 624-116. Fax: (412) 624-1172 
marker expression (e.g. major histocompatibility com-
plex [MHC] class II antigen and IL-2 receptor [IL-2R]) 
both /11 I'iiro" and following systemic immunization ill 
I'il'o 7 . FK 506 has been sh;yy~n to prevent and reverse 
human organ transplant rejection' and has recently 
been approved for the therapy of liver allograft rejec-
tion. The immunosuppressive ellieacy and safety of 
FK 506 have also been demonstrated in certain organ-
specific and systemic autoimmune diseases. both in 
animals and in preliminary clinical trials"-'.1. There 
have however. been no detailed reports of the in/lu-
enee ofFK 506 on circulating T cells in non-transplant 
patients receiving the drug. \\ie have taken the oppor-
tunity of a clinical trial of the potential etlicacy and 
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safety of FK 506 in chronic progressive mUltiple scle-
rosis (MS) to investigate the influence of the drug on 
circulating T cells in a non-transplant population that 
was otherwise in good health. 
It is widelv believed that MS is a chronic auto-
immune dise~se of the central nervous svstem (CNS), 
that is mediated by T-Iymphocytes that recognize an 
as yet unidentified autoantigen 14. MS is associated 
with abnormalities in the regulation of immune reac-
tivity, including changes in T-cell subset distribution 
that resemble those seen in other autoimmune 
diseases 14-16. Recently, significant changes in the pro-
portion of CD4 - cells expressing the CD45 isoforms 
CD45RA or CD45RO/CD29. that represent different 
maturational stages of T cells 17 have been reported in 
several autoimmune l8 .19 or immunodeficiency dis-
orders20. It has been reported that. in progressi~e MS, 
there is a selective loss of circulating CD4 + T -cells 
expressing CD45RA (2H4), a marker of 
"suppressor-inducer" (naive) cellsl~KO1K Therapies 
which may reverse this imbalance in regulatory T cell 
populations could prove valuable in the treatment of 
the disease. We have examined the intluence of FK 
506 on peripheral blood CD4 + cells expressing the 
IL-2Ra chain (CD25) and the CD45RA isoform in 19 
patients with chronic progressive MS to ascertain 
whether any observed changes might be related to 
and/or predictive of response to therapy with this 
important new anti-lymphocytic agent. 
MATERIALS AND METHODS 
SlIhjects 
The 19 patients studied were pan of a randomized. 
drug concentration-controlled pilot study of the poten-
tial etfJcacy and safety of FK 506 in chronic progres-
sive MS. The trial was approved by the University of 
Pittsburgh Medical Center (UPMC) Institutional Re-
view Board and by the US Food and Drug Adminis-
tration. Seven male and 12 female patients. age range 
25-67 years (mean 43.4 ± 10.4 years) with clinically 
dennite MS of at least one years duration and from 
whom a pretreatment and sequential. 3-monthly blood 
samples were available were studied during outpatient 
visits to the UPMC. Progressive MS with accumulat-
ing disability is a clinical pattern characterized by an 
increase in neurological impairment and disability 
over time. This definition required that each patient 
maintained a progressive pattern with accumulating 
disability in the six months before entering the study. 
Subjects with exacerbating and remitting disease with-
out progression were excluded. In order to be eligible 
tor the study. patients were at a level of disability as 
del1ned by the Kurtzke Expanded Disability Status 
Scale (EDSS)22 of grade 3.0 to 7.0 inclusive. The 
pretreatment Kurtzke scores ranged from 3.0-7.0 
(mean 5.8 ± 1.1) and the ambulation index 23 (AI) 
range (see below) was 2.0-7.0 (mean 4.5±1.3). No 
patients had received steroids and ACTH for at least 
one month, or immunosuppressive drugs for at least 3 
months at the time of entry and initial blood sampling. 
All patients were required to be co-operative and in 
otherwise good general health. In particular. subjects 
with a history of alcoholism, hepatitic disease. renal 
dysfunction. cardiac disorders. pulmonary or other 
illnesses were excluded. Normal healthy adult controls 
were laboratory volunteers of both sexes with a similar 
age range to the MS patients. 
Clinical assessment 
At entry, all patients underwent an extensive physical 
and neurological examination and a number of hema-
tological and blood chemical studies. Magnetic reso-
nance imaging (MRl) was performed to confirm the 
diagnosis of MS. General medical examination in-
cluded measurements of blood pressure, temperature, 
respiratory rate, weight, chest x-ray and electrocardio-
gram. Standard laboratory testing included the follow-
ing: blood sugar, electrolytes. blood urea. serum creat-
inine and calcium. complete blood count, coagulation 
profiles. liver screen. serum amylase and urinalysis. 
Neurological evaluation was conducted by neurolo-
gists trained in the application of the specific scoring 
systems employed during the study. Two measure-
ment svstems were used. namelY the Kurtzke (= 
EDSS) -score22 and the ambulation index (AI).n 
These scoring systems are commonly used in clinical 
trials involving MS patients. 24 The Kurtzke score 
involves the assessment of a variety of functional 
systems covering the major areas examined during 
clinical evaluation of the nervous system. Each of 
these functions is graded on a scale from 0 (normal) 
to maximum impairment (grade 6). Data from evalu-
ation of individual functional systems is then incorpo-
rated into an EDSS score which ranges from grade 0 
(normal neurological examination) to grade 10 (death 
from MS). The second clinical performance lI1dicator 
lIsed was the AI. This test focuses on the ability of the 
subject to ambulate: the grades range from 0 to 10. 
grade 0 being an asymptomatic. fully active individ-
ual while grade 10 applies to a totally bedridden 
patient. I ntervening grades are standardized to retlect 
progressive levels of impairment. 
Patients were seen initially at entry. then at weekly 
intervals for one month. thereafter at monthly inter-
vals for a period of three months. then every subse-
quent three months. Laboratory testing. a general 
medical evaluation. and neurologic functIOn were as-
sessed at each visit. 
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FK 506 administration and plasma levels 
All of the patients studied received continuous FK 506 
treatment for 11 months. After randomization into 1 
of 3 plasma concentration ranges (low. 0.1-0.3 nglml: 
medium. 0.3-0.7 nglml or high. 0.7-1.3 nglml) FK 
506 (Fujisawa Pharmaceutical Co .. Ltd .. Osaka. Ja-
pan) was started at a daily oral dose of 0.15mglkg. 
which represented half that given initially to organ 
transplant patients. This lower dose was selected to 
reduce the risk of side effects in a non-life-threatening 
condition in which there was no guarantee of thera-
peutic efficacy. Once therapy commenced. doses were 
adjusted using a dosing algorithm as described 
previously:!5. Dose reduction was allowed in the event 
of toxic side effects. The mean and median daily dose 
of FK 506 and early morning plasma trough levels of 
the drug were determined by enzyme-linked immu-
nosorbent assay26 at 0.3.6.9 and 11 months after the 
start of FK 506 administration (Table I). 
lmmunophenotypic analysis orb/ood lymphocytes 
Anticoagulated peripheral venous blood samples were 
obtained before the start of treatment (day 0) and at 7 
days. 1.3.6.9 and 11 months thereafter. Mononuclear 
cells (MNC) were isolated from the samples by centrif-
ugation over Histopaque (Sigma. S1. Louis. MO) and 
stained using standard procedures. as previously 
described6 . \!louse anti-human monocloncal antibod-
ies (mAbs) used in one or two-color !low cytometric 
analysis of patients' blood MNC or of those obtained 
from healthy adult controls included phycoerythrin 
(PE)-conjugated anti-CD4. PE-conjugated anti-CD8. 
and FITC-conjugated anti-CD15 (lL-2R. p55 a chain) 
and were diluted III 0 in Hanks' balanced salt solution 
(HBSS) with 1% bovine serum albumin (BSA) and 
0.1 % NaN,. PE-conjugated mouse IgG and FITC-
conjugated mouse IgG were used as isotopic controls. 
These antibodies were purchased from Dako. Carpin-
Table 1 Dail) dose and plasma levcl of FK 506 in MS patients 
FK SOli il 
teria, CA. To determine the proportion of CD45RA + 
cells within the CD4 + cell population. a kit containing 
FITC-conjugated T4 and RDI-conjugated anti-2H4 
was purchased from Coulter Immunology, Hialeah. 
FL. The mAbs were diluted 11 lOin the HBSSIl % 
BSA/O.I % NaN 3 buffer. Cells isolated from blood sam-
ples were incubated with diluted antibodies for 30 min 
at 4 0 C. After incubation, the cells were washed twice 
with buffer and then fixed in 1% paraformaldehyde 
until analysis by flow cytometry. Five thousand gated 
events were counted. using a FACSTAR® flow cytom-
eter (Becton-Dickinson. San Jose. CAl and the results 
were expressed as percentage positive cells. 
Statistical analyses 
The rate of change in percentage of positively staining 
cells was determined for each patient using simple 
logistic regression 27• The Wilcoxon Sign Rank test. a 
non-parametric equivalent to the paired "t"-test was 
used to compare pre-and post (12 months) FK 506 
values. as well as pre- and post-treatment indices of 
disease activity. The Wilcoxon Rank Sum test was 
used to compare pre-FK 506 values and those ob-
tained from normal volunteers. 
RESULTS 
Daily dose and plasma level o(FK 506 
The mean and median total daily dose and 12-hr 
trough plasma levels of FK 506 in the 19 MS patients 
taking the drug continuously for 12 months are shown 
in Table 1. Whilst the daily FK 506 dose rose during 
this period. the range became more restricted. Al-
though the median plasma concentration of FK 506 
remained unchanged throughout the study. there was 
\10nths after start of treatment (n; l'l) 
h l) 12 
Dosc (mg) 
mcan (SO) 
mcdian 
rang.e 
5.5(·L!) 
·+,(1 
2.0-IR.0 
5.8(2.6) 5.9( I.'l) Ii. I( 3.m 7.9(3.2) 
Plasma troug.h k\cl (ng/ml) 
mcan (SD) 
mcdian 
range 
6.0 
2.0-10.0 
03(().2) 
n.] 
O.I-0.'l 
1i.0 
2.0-10.0 
() 4( O. 3) 
n.3 
o I-\'O 
7.0 R.O 
2.0-12.0 2.0-14.0 
0.4(0.3) 0.5(0.4) 
0.3 0.3 
()[-I.I 0.1-\.::I 
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Table 2 Biochemical indices of renal impairment in FK 506-trcatcd MS patients 
Parameter 
Serum creatinine (mgJdL) 
BUN* (mgJdLl 
Baseline 
0.85 :::0.22 
12.9:::3.7 
t 12-month compared wllh basel me vatul'. 
-blood urea nitrogen. 
3 
0.94:::0.16 
13.8:::5.3 
an increase in the mean concentration from 0.3 ± 0.2 
to 0.5 ± 0.4 nglml. 
In/Illenee ofFK 506 on renal/lllletion 
Nephrotoxicity is one of the well-known potential side 
effects of FK 50628 . As shown in Table 2. the mean 
serum creatinine and blood urea nitrogen (BUN) lev-
els rose to 1.2 and 1.3 times baseline respectively. over 
the 12 months of study. 
Patient Disability 
The mean Kurtzke EDSS score and ambulation index 
in the 19 MS patients over the 12-month study period 
are shown in Table 3. The mean change in Kurtzke 
score at I year was + 0.06±0.73 (11= 19). Overall. 
there was essentially no change in either of these 
clinical indices of patient disability during the study. 
MRI data were available for the 19 patients at entry 
and at I year. The overall impression was that there 
was no quantitlable change in lesion load. 
Change in /\urt:kc score or .·If ill relatioll [() 
illt/il'iciual fila.llIlu F/\ 50n 1('1'('/.1 
As shown in Fig. I. there was a tendency to higher 
mean plasma FK 506 concentrations in those patients 
that showed improvement in Al (increase of I relative 
to baseline) or Kurtzke score (decrease of 0.5 relative 
to baseline)24 at 12 months. 
Table., Kurtzke (EOSS) and amhulatlon index IAI) scores 
Months aftcr start of treatmcnt (n = 19) 
6 9 12 p-valuc t 
0.95 :::0.20 0.92:::0.20 0.98:::0.26 0.037 
14.0:::3.2 15.5:::4.7 17.3:::5.3 0.008 
Adverse eU'eels 
The ten most common adverse events recorded in the 
FK 506-treated patients and their prevalence of occur-
rence are shown in Table 4. None of these events 
required specific treatment or necessitated withdrawal 
of patients from the study. 
Expressioll o(CD25 and CD45RA Of! peripheral 
h/ood CD4' cells 
To determine the influence of continuous systemic FK 
506 administration on the percentage of activated 
(CD25 +) and immunoregulatory (CD45RA T) CD4 .. 
lymphocytes. two-color now cytometric analysis of 
peripheral blood MNC was performed before the start 
of treatment and at intervals thereafter. up to 1 year. 
Table 5 shows that before treatment. CD4" cells and 
the CD4: CD8 ratio were elevated significantly above 
normal. unlike CD8" cells. which were significantly 
decreased in the 19 patients studied. The proportion 
of either CD4' or CDS + cells bearing the CD25 
marker was elevated above normal. as was the propor-
tion of CD45RA + CD4 - cells. When pre- and post-
treatment (12-monthl values were compared. there 
was no etfect of FK 506 on any of the parameters. 
Values obtained for CD25' and CD45RA" CD4 + 
cells during the 12-month study period are shown in 
Figure 2. There was essentially no change in the me-
dian percentages of CD25" CD4 + cells compared 
with the pretreatment level during the 12 months of 
treatment. The proportion of CD45RA + CD4" cells 
also did not change signihcantly throughout the study. 
although the median was 25% below the pretreatment 
value at 12 months. 
\-Ionths alter start or FK 506 treatment (n = 19) 
S.:ore () ~ r. 9 12 
Kurtzke 1 EDSS) 
(mean::SD) ~Kl} :!: 1.1 5.X:t: 1.2 RK~:!: U RKS~ 1.) 5.8:!: 1.3 
·\1 
(mean:: SO) 4.5::: 1.'- 4.5 :!: I.r. 4.5:!: 1.5 4 . .- :: 1.4 4.6:!: I.5 
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Table 4 The ten most common adverse reactIOns in FK 506-
treated MS patients (n = 19) 
Etlcct 
Fatiguc· 
Decreased Appetltc* 
Tremors 
Headache 
Light Sensttl\ It\ 
Blurred ViSion· 
Insomnia 
-\hdomlnal PJIn 
Hair Loss 
Hypertension 
Prevalencc ('ih) 
-1-1.4 
JH.'l 
"H.Y 
J.U 
29.-1 
27.8 
" , 
" , 
21. I 
-rna\ hI..' an 0\ t'rt''llimate Ol'cau,,"' nf lilrtkuil\ In Jitkrl'nll3tlntl JI\l'Jsl'·rl'lall'd 
,\ mptomawl0tl\ t"r()Ol drull-lndun'd l'flt'rt., 
. Inl'loc:nl'C' Dr D...Llll'nlS on gnll-h~rlDrllDnpfyc 111l'lilralllln .II I ~~:ar 
Pallel'lls o/ciIunge ill CD45R.1 - unci CD:!5 + 
CD4' cel/s in indil'idual.\lS fJ([IlClliS 
In several patients. an increase in CD45RA' ('"sup-
pressor-inducer") CD4' cells following start of FK 
506. was accompanied by a concomitant decrease in 
C025 - (activated) CD4' cells. It was of interest to 
determine whether these changes were related to grade 
of disability. Sequential determinations were therefore 
made on subjects with starting values of CD45RA • 
CD4' cells ~ 10% below the normal mean and of 
C025' C04' cells> I SO above the normal mean. 
Patients in which an increase in C045RA + C04-
cells and a decrease in C025' C04 - cells was sus-
tained for at least 2 occasions post treatment (7 sub-
jects) were examined further. Figure 3 shows that in 
this sub-group of FK 506 treated patients. there was 
no correlation between these laboratory indices of T 
cell function and the clinical assessment of patient 
disability over the follow-up period . 
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Table 5 Expression of CD25 and CD45RA on peripheral blood T cells of 19 MS patients treated with FK 506 
Antigen(s) 
CD4' 
CD8' 
CD4: CD8 
CD25' CD4-* 
CD25' CD8' 
CD45RA' CD4' 
:'-Iormal 
(n = 12) 
a 
37.8±4.5 
34.S ± 6.4 
1.1 ± 0.2 
9.3±2.1 
0.8 ±0.6 
17.2::: 7.1 
FK 506-treated 
Pre Post (12 months) 
(n = 19) (n = 19) 
I I 
b 
47.8±9.1 45.2 ± 10.2 
24.5 ± 5.4 24.6±8.3 
2.1 ±0.8 2.1 ± 1.0 
11.6 ± 6.6 12.6± 7.4 
2.5 ± 2.5 3.6 ± 3.8 
24.1 ± 10.4 20.5 ± 13.4 
-Determmed by two~olor immunofluorescence staining: value IS % CD4" or CD8" cells. as appropriate. 
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Figure 2 Percentages of CD25' CD4 - and CD45RA . CD4' cells (median values) in peripheral blood of 19 chroniC progressive 
r-IS patients at varIOUS times after the start of FK 506 immunosuppressive therapy. 
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DISCUSSION 
This investigation was designed primarily to evaluate 
the potential efficacy and toxic side etfects of FK 506 
in patients with pre-existing neurological disease. Such 
a study is of importance as there is an indication that 
FK 506 mav. under certain circumstances. be toxic to 
the nervou~ system:'!. The study was not designed 
primarily to determine the etfect of FK 506 on the 
course of MS and hence a traditionaL double-blind. 
placebo-controlled investigation was not carried out. 
Important clinical information can nonetheless be de-
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rived from a study of this natureJll . Further informa-
tion will be forthcoming once the full cohort of MS 
patients ( 105) has completed the two-year study. The 
19 patIents selected for the immunological analyses 
represented a minor proportion of the total patient 
group. While no statistical information can be drawn 
from the clinical data. the results indicate. nonethe-
less. that in these patIents. at least clinical stability was 
c\ident throughout the course of treatment. Patients 
were chosen on the basis of chronic disease progres-
sian and all had deteriorated by at least one score on 
the Kurtzke EDSS during the year before FK 506 
administration. The mean change in Kurtzke score in 
the 19 FK 506-treated patients after 12 months was + 
0.06 ± 0.73. Thus. the results show a trend to stabiliza-
tion of the MS while on FK 506 treatment. There was 
also a tendency to a higher mean plasma FK 506 level 
in those patients that showed improvement in Kurtzke 
score (decrease of 0.5 relative to baseline). The side 
effects of the drug were mild in the 19 patients. and in 
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no case were they deemed severe enough to warrant 
discontinuation of the medication. 
The present study focuses on the influence of FK 
506 on circulating T cells in chronic progressive MS. 
Previous studies have shown that activated T -cells are 
increased in the peripheral blood of patients with this 
condition J I. Moreover. T -cells expressing cell surface 
activation molecules. such as IL-2R and MHC class II 
antigens. can be identified in lesional tissue within the 
CNS of MS patientsJ2 . In the present investigation. 
significantly increased incidences both in circulating 
total C04 + cells and in the C04: C08 ratio were 
observed in the 19 progressive MS patients compared 
with healthy adult control subjects. Increases both in 
activated C025 + C04 + and C025 + C08 + T cells 
(especially) were also found compared with healthy 
age- and sex-matched individuals. These findings sug-
gested impaired immune regulation. consistent with 
previous reports of T cell populations in this disease. 
In contrast with an earlier study"l. and our own previ-
ous observations on a smaller group of these 
patientsJJ • the mean proportion of immunoregulatory 
C045RA + C04 + cells in peripheral blood was not 
decreased significantly pretreatment compared with 
healthy subjects. There was however. considerable 
inter-individual variation in this parameter. Several 
patients showed a decrease (> 10%) in this subset of 
C04 + cells that has been correlated positively with 
T-cell suppression and with inhibition ofT- and B-cell 
clones reactive with elements of the CNS 21 • 
Treatment with FK 506. a potent inhibitor of C04 + 
T-cell activation in response to stimulation via the 
C03/T cell receptor pathway. did not atfect signifi-
cantly the proportion of either C025' or C045 RA . 
C04 ~ cells over a 12-month period. ~loreoverK no 
relationship could be demonstrated between an in-
crease in Cl~RoA - C04 + cells together with a con-
comitant decrease in C025' C04' cells and the 
patients' disability status in response to FK 506. No-
tably. at the FK 506 doses used and at the plasma 
levels achieved (which are anti-lymphocytic 111 
l'ill"O.l.l.5.b and similar to or lower than those reported 
previously in patients with uveitis.14. or psoriasis"l 
there was no significant overall change in the clinical 
status of the MS patients. 
While this study has examined the int1uence of FK 
506 on non-specific indices of peripheral hlood C04 + 
cell activation and function. the possibility that this 
new anti-T cell agent might exert elfects on the func-
tion of specific. disease-associated T cells hoth within 
the hlood and more significantly. within the eNS. 
cannot be excluded. Indeed. local inhibition of in-
tlammatorv events within the skin have recentlv been 
repofted i;l FK RMS-tre~lted psoriasis patients.·1115 .1(, 
Although FK 506 has not been detected in the cere-
brospinal fluid of several organ transplant patients 
with very high plasma drug [e\'els exhibiting toxic 
manifestations of FK 506 (R. Venkataramanan. Dept. 
of Pharmacy. University of Pittsburgh: personal com-
munication) studies on T-cell populations within le-
sional tissue of FK 506-treated patients with pre-
eXlst1l1g neurological disease would be very 
informative. 
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